Categories: Tech

Topicus.com Inc. Announces Release Date for Third Quarter Results

 | Source: Topicus.com Inc.

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) — Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2025.

The Company’s quarterly results will be disseminated via press release and made available on the Company’s website (www.topicus.com) and the SEDAR website (www.sedarplus.ca), after markets close on Tuesday, November 4, 2025.  

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol “TOI”. Topicus acquires, manages and builds vertical market software businesses.

Contact:

Jamal Baksh
Chief Financial Officer
416-861-9677

GlobeNews Wire

Recent Posts

ProFrac Holding Corp. Reports Third Quarter 2025 Results

WILLOW PARK, Texas--(BUSINESS WIRE)--ProFrac Holding Corp. (NASDAQ: ACDC) (“ProFrac”, or the “Company”) today announced financial…

17 minutes ago

Palabra AI Acquires Talo and Launches Suite of Real-Time Multilingual Communication Products

LONDON--(BUSINESS WIRE)--Palabra AI, the company behind sub-second speech-to-speech translation, today announced the acquisition of Talo…

17 minutes ago

FPT APPOINTS ABES AS ITS FIRST DISTRIBUTOR IN INDIA TO EXPAND ITS MARKET PRESENCE

TURIN, Italy, Nov. 10, 2025 /PRNewswire/ -- FPT, the Iveco Group brand dedicated to the design, production,…

18 minutes ago

Torch Relay for the 15th National Games Kicks Off, with Feng Xingya, Chairman and President of GAC Group, Serving as Torchbearer

HONG KONG, Nov. 2, 2025 /PRNewswire/ -- On November 2, the torch relay for the…

18 minutes ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents…

3 hours ago

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting 2025

Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety…

3 hours ago